Abstract:Abstract Background: Tumor specific antigen (TSA) identification in human cancer predicts response to immunotherapy and provides vaccine targets for precision medicine. In addition to neoantigens from somatic coding mutations, numerous non-mutated TSAs can elicit T-cell responses but are often overlooked by current methods. We present a method that accurately and comprehensively predict TSAs from RNAseq data regardless of mutation status. Methods: HLA-I genotypes were predicted with seq2HLA. RNAseq fastq files were translated into all possible peptides of length 8-11, and peptides with high expression in the tumor and comparatively low expression in normal were tested for their MHC-I binding potential with netMHCpan-4.0. We defined our predicted TSA by i) high expression in tumor samples, ii) low expression in normal samples, and iii) high predicted patient-specific MHC-I binding affinity. Results: We developed a novel pipeline for TSA prediction from RNAseq that is not limited to mutation-derived TSAs. This pipeline was used to predict all possible unique peptides size 8-11 on previously published murine and human lung and lymphoma tumors then validated on matched tumor and control lung adenocarcinoma (LUAD) samples. This pipeline is able to predict TSAs in MHC-I ligand-purified proteomics data with favorable performance to existing methods. Furthermore, neoantigens predicted by exomeSeq are typically poorly expressed at the RNA level, (28% of predicted neoantigens with >0 expression, mean of 15.6 reads/sample) and a fraction of them (47/6,928, 0.68%) are expressed in matched normal samples. Finally, a set of 6 TSAs are expressed in 22/39 (56%) of LUAD tumors and represent attractive vaccine targets. Conclusion: Direct quantification of RNAseq evidence of the potential peptidome in matched tumor and control RNAseq samples, via our novel pipeline, allows for exhaustive detection of TSAs. Citation Format: Michael Sharpnack, Travis Johnson, Robert Chalkley, Zhi Han, David Carbone, Kun Huang, Kai He. Exhaustive tumor specific antigen detection with RNAseq [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 238.

Hepa And Parse Systematic Discovery Of Clinically Relevant Tumor-Specific Antigens

HEPA and PARSE

An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Figures 1-5 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 3 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Mapping the High Throughput Serex Technology Screening for Novel Tumor Antigens

HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma.

Supplementary Table 4 from An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer

TSAFinder: Exhaustive Tumor-Specific Antigen Detection with RNAseq

Genome-Scale Search of Tumor-Specific Antigens by Collective Analysis of Mutations, Expressions and T-Cell Recognition

Using Immunoproteomics to Identify Tumor-Associated Antigens (taas) As Biomarkers in Cancer Immunodiagnosis.

Evolution of the Strategies for Screening and Identifying Human Tumor Antigens.

TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.

HLA-A2–Restricted Cytotoxic T Lymphocyte Epitopes from Human Heparanase as Novel Targets for Broad-Spectrum Tumor Immunotherapy

Tsnad: an Integrated Software for Cancer Somatic Mutation and Tumour-Specific Neoantigen Detection

Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

The Screening, Identification, Design and Clinical Application of Tumor-Specific Neoantigens for TCR-T Cells

Abstract 238: Exhaustive Tumor Specific Antigen Detection with RNAseq

Caatlas: an Immunopeptidome Atlas of Human Cancer.

Tumour-associated antigens and their anti-cancer applications.

Antigen discovery for the development of cancer immunotherapy